Bevacizumab After Chemoradiotherapy For Locally Advanced Lung Adenocarcinoma

Inclusion Criteria:

• Pathologic confirmation of lung adenocarcinoma
• Patients have measurable or evaluable lesions based on the Response EvaluationCriteria in Solid Tumors (RECIST) criteria.
• Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
• Unresectable, refusing surgery or after R2 surgery ,confirmed by PET-CT or chest andabdominal CT, craniocerebral MRI, and ECT.
• After radiotherapy and chemotherapy, the tumor is in partial remission, completeremission or stable.
• 1-2 months after chemoradiotherapy ends.
• Organ and bone marrow functions were normal within the first 30 days of enrollment,including: • AST, ALT≤ 2.5ULN or ≤5ULN (with liver metastasis); • TBil ≤ 1.5 ULN •neutrophils absolute value ≥500 cells/mm3 • creatinine clearance ≥45 mL/min ;•platelets≥50,000 cells/mm3.
• CB6 within normal limits
• Patients and their family signed the informed consents

Exclusion Criteria:

• Lung squamous carcinoma.
• The tumor has completely approached, encircled, or invaded the intravascular space ofthe great vessels (e.g., the pulmonary artery or the superior vena cava).
• The tumor was associated with a cavity over 2cm in diameter.
• Bleeding tendency or coagulation disorder.
• Patients with hemoptysis (1/2 teaspoon blood/day) within 1 month.
• Full-dose anticoagulation therapy was used within the past 1 month.
• Severe vascular disease occurred within 6 months.
• Gastrointestinal fistula, perforation or abdominal abscess occurred within 6 months.
• Hypertensive crisis, hypertensive encephalopathy, symptomatic heart failure (New Yorkclass II or above), active cerebrovascular disease or cardiovascular disease occurredwithin 6 months.
• Uncontrolled hypertension (systolic > 150mmHg and/or diastolic > 100mmHg).
• Major surgery within 28 days or minor surgery or needle biopsy within 48 hours.
• Urine protein 3-4+, or 24h urine protein quantitative >1g.
• Degree 3 esophagitis after chemoradiotherapy has not recovered.
• Elderly patients (age 75 years).
• The investigator does not consider the participant to be eligible for this study.